Integrated Investment Consultants LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Integrated Investment Consultants LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the fourth quarter, Holdings Channel reports. The firm owned 609 shares of the biopharmaceutical company’s stock after purchasing an additional 39 shares during the period. Integrated Investment Consultants LLC’s holdings in Regeneron Pharmaceuticals were worth $434,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in REGN. Brighton Jones LLC grew its position in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 14 shares in the last quarter. Ieq Capital LLC grew its position in shares of Regeneron Pharmaceuticals by 10.1% during the 2nd quarter. Ieq Capital LLC now owns 5,531 shares of the biopharmaceutical company’s stock valued at $5,814,000 after purchasing an additional 507 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its position in shares of Regeneron Pharmaceuticals by 25.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,980 shares of the biopharmaceutical company’s stock valued at $3,132,000 after purchasing an additional 612 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Regeneron Pharmaceuticals by 7.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 134,762 shares of the biopharmaceutical company’s stock valued at $141,639,000 after purchasing an additional 9,472 shares in the last quarter. Finally, AE Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 19.4% during the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 89 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on REGN shares. Bank of America reissued an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $681.58 on Friday. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The company has a 50-day moving average price of $738.60 and a 200-day moving average price of $949.99. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.